Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
NKE enters the post-earnings week with shorts quietly retreating, borrow costs climbing, and a stock that has now lost 11% over the past month after a muted reaction to a deeply disappointing fiscal Q1 print.
The most striking change since last week's earnings coverage is the sharp unwind in short interest. The previous notes documented a short position built to 8.2% to 8.4% of the free float through September, the most aggressive accumulation in recent memory for a name this size. That position has collapsed. SI now reads just 0.014% of the free float, a drop of 27% over the past week. The absolute share count, roughly 201,000, is a fraction of the near-100 million shares short that appeared in the ORTEX data around earnings day. This is a dramatic change in the data and a material one: the aggressive bear campaign that defined the October 1 earnings setup has, at least in aggregate terms, been largely unwound in the days that followed. What has not followed is any price recovery. The stock closed Friday at CAD 6.06, down 5% on the week and down 11% over the month.
Note on data: The snapshot presented here reflects the TSX-listed Canadian depositary receipt or a secondary listing rather than the primary NYSE-listed share, where NKE last traded near USD 35. The CAD 6.06 price and the very low absolute share counts in short interest reflect this secondary listing. The short interest and borrow data should be read in that context, not as a direct read on the NYSE position described in prior notes.
The borrow market for the TSX instrument is telling a different story from the SI trend. Cost to borrow has risen sharply, up 31% over the past week to 5.68% and nearly doubling over the past month from a base of around 2.9%. That rate of increase is notable on its own terms: the cost to borrow was below 2% in early September and has since climbed steadily through 3%, 4%, and now past 5.5%. Borrow costs rising while short interest falls is an unusual combination. It can reflect tightening availability in the lending pool for this specific instrument, or it can reflect that the remaining shorts are paying more to hold a position that has become harder to finance. Either way, the direction of travel in borrow cost is worth tracking.
The factor score picture reflects a stock under genuine fundamental pressure. EPS momentum ranks in the 11th percentile over 30 days and the 16th percentile over 90 days, two of the weakest readings in the footwear sector. Forward earnings growth ranks in just the 4th percentile. The short score of 29.3 is actually low by absolute standards, consistent with the dramatic SI unwind, and places NKE in the 21st percentile of its short-score rank. The dividend score at the 89th percentile is the sole standout, though the most recent dividend data in the snapshot dates to May 2022, suggesting that figure should be treated with caution given the operational and financial reset the company is undergoing.
The institutional picture shows founder Philip Knight still holds 17.7% of shares, providing a long-term anchor. Capital Research added over 16 million shares as of end-August, and State Street added roughly 4 million in the same period, while Morgan Stanley trimmed 3.3 million shares as of end-June. The net institutional flow is not a distress signal, but it is not a strong conviction buy either. The December 17 earnings date is the next formal catalyst, leaving roughly ten weeks for the market to assess whether the turnaround narrative, damaged further by the October 1 print and the 26% Greater China revenue decline, has any near-term support.
The question heading into December is less about whether Nike's long-term brand equity is intact and more about whether the pace of the operational reset is accelerating or stalling, and whether borrow costs on this instrument continue to climb as the post-earnings dust settles.
See the live data behind this article on ORTEX.
Open NKE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
